17 GHP Healthcare and Pharmaceutical Awards 2025 ver the past thirty years, Sudhir Agrawal, D.Phil., has been developing a new class of medicines called genetic medicines. In this approach, the medicine is designed to locate disease-related RNA in the body and attach to it like Velcro, thereby stopping the production of disease-causing proteins. This attachment occurs through a process called hybridization. This approach is unique because the medicine can be created based on genetic information. The number of drugs in this class is now approved for treating genetic disorders such as Duchenne muscular dystrophy, spinal muscular atrophy, and others. The main components of this class of medicines include a short fragment of DNA or RNA, which is the mirror image of diseaserelated RNA, along with chemical modifications that provide the sequence with drug-like properties. The past work carried out by Dr. Agrawal on chemical modifications is widely used in creating genetic medicines. It has enabled the approval of drugs for several indications, including liver diseases and CNS disorders. In 2017, Dr. Agrawal founded Arnay Sciences to improve chemical modifications, making this type of medicine more widely accessible. He describes this work as chemical engineering because it combines chemistry and engineering to create circular shapes of genetic medicines. In simple terms, these circular genetic medicines can roam around in the body until they find the disease-associated RNA. In lab testing, circular genetic drugs show increased potency and specificity. He has filed several patents claiming the new design of genetic medicines. Arnay’s mission is to make these innovations accessible to researchers worldwide for developing genetic medicines. In 2022, Arnay signed a licensing and collaboration agreement with Alloy Therapeutics (Waltham, MA), whose business model aims to democratize drug discovery platforms. Alloy has partnered with Sanofi to use Arnay’s discoveries in developing a medicine for brain disease. Arnay Sciences has a distinctive business model. Sudhir Agrawal is the Founder and President, and the sole individual in the company. He develops research ideas and executes them with the support of contract research organizations. His research has extensive implications in developing genetic medicines. Dr. Agrawal earned his D.Phil. in chemistry and shifted to biology during his postdoctoral research at the MRC Laboratory of Molecular Biology in Cambridge, UK. He has published over 300 research papers, authored over 400 patents worldwide, and has edited four books. He has been awarded the Lifetime Achievement Award in 2023 by the Oligonucleotide Therapeutic Society. Arnay Sciences is a life sciences research practice focused on the chemical engineering of DNA and RNA to develop genetic medicines. We learn more about Founder and President Sudhir Agrawal, D.Phil. and the practice as Arnay Sciences secures its award in our Healthcare and Pharmaceutical Awards 2025. Best Life Science Research Practice 2025 – Northeast USA It’s an honour to award Arnay Sciences with its prestigious title of Best Life Science Research Practice 2025 – Northeast USA and we sincerely wish the practice all the best for the years to come. Contact: Sudhir Agrawal, D.Phil. Company: Arnay Sciences Website: https://arnaysciences.com/ O AIS-Aug25231
RkJQdWJsaXNoZXIy NTY1MjM3